The study investigates the efficacy of Colla corii asini (CCA) in treating anemia in pregnant women with beta-thalassemia, a significant health concern in regions with high thalassemia prevalence, such as Southern China. The potential market for CCA as a therapeutic agent could be substantial, given the lack of safe and effective treatments for this demographic. The findings may position CCA as a viable alternative to conventional therapies, which often have severe side effects. Competitive analysis indicates a niche market with limited direct competition in the use of traditional Chinese medicine for this indication, presenting an opportunity for differentiation and market entry. Diligence implications include the need for thorough evaluation of safety and efficacy data, as well as potential regulatory pathways for traditional medicine integration into standard care.